Frontlight ResearchEarly access
Active, not recruitingPhase 1
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTIPLE RISING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF DEURUXOLITINIB IN HEALTHY ADULTS
Key facts
- Who runs it
- Sun Pharmaceutical Industries Inc.
- Where
- Romania1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 36 people, planned
- Started
- 19 Nov 2025
- Ended
- 1 Sept 2026
- Type of study
- Interventional
- Record updated
- 22 September 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Record updated
- 22 September 2026